Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 391-401 , June 2009

Adverse effects of therapy for ANCA-associated vasculitis

  • Jennifer Turnbull, MSci (Hons), MBChB (Hons), Doctor
    • ,
  • Lorraine Harper, PhD, MRCP, Doctor

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 121 414 7042; Fax: +44 121 627 2527.

References 

  1. Morgan MD, Harper L, Williams J, et al. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol. 2006;17(5):1224–1234[Epub 2006 Apr 19]
  2. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004–1010[Epub 2007 Oct 2]
  3. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. 2008.
  4. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16:2018–2027
  5. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–2188[Epub 2007 Jun 20]
  6. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–2469
  7. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44
  8. Flossmann O, Jayne DR. Maintaining remission in a patient with vasculitis.
  9. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41(4):776–784
  10. Anderson G, Coles ET, Crane M, et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med. 1992;83(302):427–438
  11. Hoffman GS, Drucker Y, Cotch MF, et al. Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum. 1998;41(12):2257–2262
  12. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in155 patients. Arthritis Rheum. 2000;43:1021–1032
  13. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patients. Rheumatology (Oxford). 2005;44(4):495–501
  14. Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76–85
  15. Guillevin L, Cordier J, Lohte F, et al. A prospective, multi-centre randomised trial comparing steroids and pulse cyclophosphomide versus steroids and oral cyclophosphomide in the treatment of generalised Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187–2198
  16. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Int Med. 1992;116:488–498
  17. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351–361
  18. Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener's granulomatosis: analysis of 113 patients.
  19. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41(10):1828–1834
  20. Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination.
  21. Stassen PM, Sanders JS, Kallenberg CG, et al. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2008;23(2):654–658[Epub 2007 Oct 2]
  22. Hellmich B, Schnabel A, Gross W. G-CSF treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Arthritis Rheum. 1999;42:1752–1756
  23. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995;151(3 Pt 1):795–799
  24. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780–789
  25. Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol. 2007;26(5):663–670[Epub 2006 Dec 21]
  26. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21(2):246–251
  27. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487–2498
  28. Chung JB, Armstrong K, Schwartz JS, et al. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000;43(8):1841–1848
  29. Stegeman C, Cohen Tervaert J, de Jong P, Kallenberg C. for the Dutch Cotrimoxazole Wegener's Study Group. Trimethoprim-sulfamethoxazole for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335:16–20
  30. Wung P, Holbrook J, Hoffman G, et al. Risk factors for Herpes Zoster in immunocompromised patients: experience from the Wegener's granulomatosis etanercept trial. Kidney Blood Press Res. 2005;28:175
  31. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis. 2004;4(1):26–33
  32. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284
  33. Stassen PM, Derks RP, Kallenberg CG, et al. Venous thromboembolism in ANCA-associated vasculitis – incidence and risk factors. Rheumatology (Oxford). 2008;47(4):530–534
  34. Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620–626
  35. Dubertret L. Methotrexate in dermatology and rheumatology. Joint Bone Spine. 2005;72(2):104–105
  36. Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114(6):463–469
  37. Perri D, Cole DE, Friedman O, et al. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J. 2007;30(5):1014–1017
  38. Reinhold-Keller E, Schmitt WH, Gross WL. Azathioprine toxicity mimicking a relapse of Wegener's granulomatosis. Rheumatology (Oxford). 2001;40(7):831–832
  39. Wung PK, Anderson T, Fontaine KR, et al. Effects of corticosteroids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum. 2008;59(5):746–753
  40. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52(7):2168–2178
  41. Exley AR, Bacon PA, Luqmani RA, et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol. 1998;37(1):57–63
  42. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford). 2002;41(5):572–581
  43. Boomsma MM, Stegeman CA, Kramer AB, et al. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int. 2002;13(1):74–82
  44. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–430
  45. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing corticosteroids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49(1):93–100
  46. Clowes JA, Peel N, Eastell R. Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2001;13(4):326–332
  47. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383–1389
  48. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039
  49. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657–666
  50. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD004523
  51. Booth AD, Wallace S, McEniery CM, et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum. 2004;50(2):581–588
  52. de Leeuw K, Sanders JS, Stegeman C, et al. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis. 2005;64(5):753–759[Epub 2004 Sep 16]
  53. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109(14):1718–1723[Epub 2004 Mar 22]
  54. Domsic R, Maksimowicz-McKinnon K, Manzi S. Prevention of cardiovascular disease in patients with rheumatic diseases. Best Pract Res Clin Rheumatol. 2006;20(4):741–756
  55. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–1808
  56. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842–852
  57. Pankhurst T, Savage CO, Gordon C, et al. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004;43(12):1532–1535[Epub 2004 Aug 17]
  58. Tatsis E, Reinhold-Keller E, Steindorf K, et al. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum. 1999;42(4):751–756
  59. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002;100(1):82–85
  60. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–105[Epub 2007 Oct 15]
  61. Hellmich B, Kausch I, Doehn C, et al. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?. Ann Rheum Dis. 2004;63(10):1183–1185
  62. Helfand M, Mahon SM, Eden KB, et al. Screening for skin cancer. Am J Prev Med. 2001;20(3 Suppl.):47–58
  63. Nath R, Mant C, Luxton J, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007;57(4):619–625
  64. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol. 2008;35(1):11–13
  65. Beckman N, Waern M, Gustafson D, et al. Secular trends in self reported sexual activity and satisfaction in Swedish 70 year olds: cross sectional survey of four populations, 1971–2001. BMJ. 2008;337:a279
  66. Vroom F, de Walle HE, van de Laar MA, et al. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf. 2006;29(10):845–863
  67. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis. 2004;43(5):772–781
  68. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody--associated vasculitis. A randomized trial. Ann Intern Med. 2009;150:670–680

PII: S1521-6942(09)00043-6

doi: 10.1016/j.berh.2009.04.002

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 391-401 , June 2009

Article Tools